These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 37945977)
1. A Systematic Review of Novel Therapies of Pulmonary Arterial Hypertension. Nabeh OA; Saud AI; Amin B; Khedr AS; Amr A; Faoosa AM; Esmat E; Mahmoud YM; Hatem A; Mohamed M; Osama A; Soliman YMA; Elkorashy RI; Elmorsy SA Am J Cardiovasc Drugs; 2024 Jan; 24(1):39-54. PubMed ID: 37945977 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of clinical efficacy of fasudil for the treatment of pulmonary arterial hypertension. Raja SG Recent Pat Cardiovasc Drug Discov; 2012 Aug; 7(2):100-4. PubMed ID: 22670803 [TBL] [Abstract][Full Text] [Related]
3. Haemodynamic effects of PAH-targeted therapies in pulmonary hypertension due to lung disease: A systematic review and meta-analysis. Farmakis IT; Vazakidis P; Doundoulakis I; Arvanitaki A; Zafeiropoulos S; Boutou A; Karvounis H; Giannakoulas G Pulm Pharmacol Ther; 2021 Jun; 68():102036. PubMed ID: 33979684 [TBL] [Abstract][Full Text] [Related]
5. The Rho kinase 2 (ROCK2)-specific inhibitor KD025 ameliorates the development of pulmonary arterial hypertension. Yamamura A; Nayeem MJ; Sato M Biochem Biophys Res Commun; 2021 Jan; 534():795-801. PubMed ID: 33160621 [TBL] [Abstract][Full Text] [Related]
6. Sotatercept for Pulmonary Arterial Hypertension in the Inpatient Setting. Torbic H; Tonelli AR J Cardiovasc Pharmacol Ther; 2024; 29():10742484231225310. PubMed ID: 38361351 [TBL] [Abstract][Full Text] [Related]
7. Prostaglandin and prostaglandin receptors: present and future promising therapeutic targets for pulmonary arterial hypertension. Zeng C; Liu J; Zheng X; Hu X; He Y Respir Res; 2023 Nov; 24(1):263. PubMed ID: 37915044 [TBL] [Abstract][Full Text] [Related]
8. LncRNA-SMILR modulates RhoA/ROCK signaling by targeting miR-141 to regulate vascular remodeling in pulmonary arterial hypertension. Lei S; Peng F; Li ML; Duan WB; Peng CQ; Wu SJ Am J Physiol Heart Circ Physiol; 2020 Aug; 319(2):H377-H391. PubMed ID: 32559140 [TBL] [Abstract][Full Text] [Related]
9. [Evolution of pathogenetic therapy of pulmonary arterial hypertension]. Chazova IE; Yarovoy SY; Danilov NM Ter Arkh; 2019 Dec; 91(12):4-9. PubMed ID: 32598582 [TBL] [Abstract][Full Text] [Related]
10. Novel Mechanisms Targeted by Drug Trials in Pulmonary Arterial Hypertension. Condon DF; Agarwal S; Chakraborty A; Auer N; Vazquez R; Patel H; Zamanian RT; de Jesus Perez VA Chest; 2022 Apr; 161(4):1060-1072. PubMed ID: 34655569 [TBL] [Abstract][Full Text] [Related]
11. New and Emerging Therapeutic Drugs for the Treatment of Pulmonary Arterial Hypertension: A Systematic Review. Rasheed A; Aslam S; Sadiq HZ; Ali S; Syed R; Panjiyar BK Cureus; 2024 Aug; 16(8):e68117. PubMed ID: 39347150 [TBL] [Abstract][Full Text] [Related]
12. Evidence synthesis in pulmonary arterial hypertension: a systematic review and critical appraisal. Schlueter M; Beaudet A; Davies E; Gurung B; Karabis A BMC Pulm Med; 2020 Jul; 20(1):202. PubMed ID: 32723397 [TBL] [Abstract][Full Text] [Related]
13. Assessment of Clinical Worsening End Points as a Surrogate for Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Tremblay É; Gosselin C; Mai V; Lajoie AC; Kilo R; Weatherald J; Lacasse Y; Bonnet S; Lega JC; Provencher S Circulation; 2022 Aug; 146(8):597-612. PubMed ID: 35862151 [TBL] [Abstract][Full Text] [Related]
14. Canagliflozin inhibits PASMCs proliferation via regulating SGLT1/AMPK signaling and attenuates artery remodeling in MCT-induced pulmonary arterial hypertension. Chen X; Yu X; Lian G; Tang H; Yan Y; Gao G; Huang B; Luo L; Xie L Biomed Pharmacother; 2024 May; 174():116505. PubMed ID: 38574614 [TBL] [Abstract][Full Text] [Related]
15. Metformin Prevents Progression of Experimental Pulmonary Hypertension via Inhibition of Autophagy and Activation of Adenosine Monophosphate-Activated Protein Kinase. Liu Y; Xu Y; Zhu J; Li H; Zhang J; Yang G; Sun Z J Vasc Res; 2019; 56(3):117-128. PubMed ID: 31085922 [TBL] [Abstract][Full Text] [Related]
16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 5 inhibitors for pulmonary hypertension. Barnes H; Brown Z; Burns A; Williams T Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012621. PubMed ID: 30701543 [TBL] [Abstract][Full Text] [Related]
18. Recent progress in the treatment of pulmonary arterial hypertension: expectation for rho-kinase inhibitors. Fukumoto Y; Tawara S; Shimokawa H Tohoku J Exp Med; 2007 Apr; 211(4):309-20. PubMed ID: 17409670 [TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness of Sotatercept and Approved Add-On Pulmonary Arterial Hypertension Therapies: A Systematic Review and Network Meta-Analysis. Pitre T; Desai K; Mah J; Zeraatkar D; Humbert M Ann Am Thorac Soc; 2024 Aug; 21(8):1194-1203. PubMed ID: 38820258 [No Abstract] [Full Text] [Related]
20. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. Hoeper MM; Badesch DB; Ghofrani HA; Gibbs JSR; Gomberg-Maitland M; McLaughlin VV; Preston IR; Souza R; Waxman AB; Grünig E; Kopeć G; Meyer G; Olsson KM; Rosenkranz S; Xu Y; Miller B; Fowler M; Butler J; Koglin J; de Oliveira Pena J; Humbert M; N Engl J Med; 2023 Apr; 388(16):1478-1490. PubMed ID: 36877098 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]